ArticleCancer medicine2025
Prognostic Value of Pre-Treatment Diffusion Kurtosis Imaging for Progression-Free Survival Prediction in Advanced Nasopharyngeal Carcinoma.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multiparametric MRI for Assessing the Tumor Microenvironment in Head and Neck Cancer: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- The prognostic value of intra- and peritumoral habitat analysis in nasopharyngeal carcinoma: combining IVIM and ASL.European radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study aimed to evaluate the value of diffusion kurtosis imaging (DKI) for prognostic value for long-term PFS in nasopharyngeal carcinoma (NPC).
methodsA cohort of 295 NPC patients underwent pretreatment 3.0T MRI with DKI to derive mean kurtosis (MK), mean diffusion (MD), and apparent diffusion coefficient (ADC). Clinical parameters (Tumor stage, EBV-DNA, neoadjuvant chemotherapy regimens) were recorded. Follow-up extended to December 2023. Statistical analyses (R software v4.3.0) included univariate/multivariate Cox regression and Kaplan-Meier survival analysis. A prognostic nomogram integrating key predictors was developed.
resultsMedian 10-year follow-up revealed 2-, 5-, and 10-year PFS rates of 89%, 79%, and 74%, respectively. Univariate Cox regression analysis demonstrated that T stage, Clinical Stages, NAC regimens, ADC_Group, MK_Group, and MD_Group were significant prognostic factors for PFS in NPC (p < 0.05). Multivariate analysis identified Clinical Stage (HR = 2.230, 95% CI 1.44-3.66, p < 0.001), NAC (neoadjuvant chemotherapy) regimens (HR = 0.56, 95% CI 0.35-0.90, p = 0.017), and MK_Group (HR = 0.52, 95% CI 0.33-0.82, p = 0.003) as independent prognostic factors. The MK_Group high exhibited superior survival rates versus MK_Group low (2-year: 94% vs. 81%; 5-year: 85% vs. 66%; 10-year: 79% vs. 64%; all p < 0.05). The nomogram combining Clinical Stage, NAC, and MK_Group demonstrated moderate predictive accuracy for 2-, 5-, and 10-year PFS (AUC = 0.736, 0.718, 0.697).
conclusionPretreatment MK serves as a robust noninvasive biomarker for long-term PFS in NPC. Integration with Clinical Stage and NAC regimens enhances prognostic stratification, supporting personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.